ICHIHARA Kiyoshi Kawasaki Medical School, Medicine, Associate Professor, 医学部, 助教授 (10144495)
TANAKA Katsuhiro Kawasaki Medical School, Medicine, Assistant Professor, 医学部, 講師 (90289174)
SONOO Hiroshi Kawasaki Medical School, Medicine, Professor, 医学部, 教授 (60136249)
|Budget Amount *help
¥2,100,000 (Direct Cost : ¥2,100,000)
Fiscal Year 1998 : ¥900,000 (Direct Cost : ¥900,000)
Fiscal Year 1997 : ¥1,200,000 (Direct Cost : ¥1,200,000)
1.Translations of the quality-of-life (QOL) questionnaires developed in western countries which were frequently used in many cancer clinical trials and their cross-cultural validation
(1)The translations of the EORTC QLQ-BR23 (breast cancer subscale), FACT-B (breast cancer subscale), and FACT-Taxane were completed. They are used in a phase III ranndomized trials comparing two types of post-surgial adjuvant chemotherapy for breast cancer patient (NSAS-BC).
(2)Semi-fical translations of the FACT-Sp (spiritual well-being), 0 (ovarian cancer), Cx (cervical cancer), C (colorectal cancer), P (pancreas cancer). E (seophageal cancer), ACT (anorexiafcachexia), and ES (estrogen-related symptoms) were completed. They are in the process of pilot-testing.
2.The results of the psychometric properties (acceptability, reliability, validity, and sensitivity) of the two QOL questionnaire measures, that is, EORTC QLQ-C30 and the QOL-ACD, for Japanese cancer patients will be presented in the 35th Annual Meeting of the American Society fo Clinical Oncology (ASCO) and the 7th Annual Meeting of the Japanese Breast Cancer Society in May, 1999. Papers onthese subjects will be submitted in a near future.
3.The results of the detailed assessnents of treatment-related symptoms, psychological destress, and QOL in post-surgical breast cancer patients in Los Angels, and the analyses of predictive factors of their QOL were reported in a paper (Breast Cancer Res and Treat, in press). We geban similar study for Japanese patients.
4.The paper investigating the prognostic significance of QOL scores is in submission.
5.We began the study investigating the risk and and benefit of beast cancer patients receiving adjuvant therapies using Markov decision models in which patients-administered QOL scores assessed by EuroQol, FACT, and Time Trade-off (TTO) will be imputed. The endpoint of the study is cost/QALY (Quality-adjusted life year).